Today’s new data on DDS-04 (a series of antibiotics against Enterobacteriaceae, a group of pathogens classified as High-Priority by the WHO) confirms that the series represents a high-potential addition to Summit’s emerging pipeline of new-mechanism antibiotics. We look forward with interest to further developments, including the selection of a preclinical candidate, and reiterate our positive stance.
